entertainment -WSS

entertainment

author：explore 2025-09-28 02:31:54 - browse：5799

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Life science postdocs should get big pay hike, NIH panel says

entertainment

Wikipedia

WSS

At JPM 2024, hospital systems pitch financial strength to investors

Life science postdocs should get big pay hike, NIH panel says

$1 billion proposal to grow Boston, Massachusetts biotech

Readout Newsletter: BridgeBio, Akero, and human embryo models

A preacher's new calling: Diversifying neuroscience research

Why Talkspace is targeting Medicare, a tricky market

focus

entertainment

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Jerome Adams on the need for new antivirals for Covid

Harvard's David Sinclair gets blowback over aging

Duchenne breakthrough therapy leaves behind pioneering families

Ancient Greek ideas underpin modern concepts of pregnancy

As demand for Covid shots wanes, Moderna seeks its next success

Profiling embryos to choose those with higher IQs is almost a reality

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Does Paxlovid work in people vaccinated against Covid

focus

Pregnant women don't need prenatal multivitamins, study concludes

Study suggests new cause of Down syndrome: cells linked to aging

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

FDA early review: GLP

Families look for replacement for GSK asthma drug Flovent

A preacher's new calling: Diversifying neuroscience research

explore

entertainment

Wikipedia

hotspot